IDH1 and glioblastoma: Patient 5, a 69 year-old man with a recurrent GBM (IDH1/2 wild type, methylated MGMT promoter), had tumor progression on a clinical trial consisting of IMRT/TMZ, then TMZ and vorinostat (a histone deacetylase inhibitor).